Tyrosine

Tyrosine

SCHEMBL3485476

NCCCC[C@H](N)C(=O)Oc1ccc(C[C@H](N)C(=O)O)cc1.N[C@@H](Cc1ccc(O)cc1)C(=O)O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGB3 P05106 2/20 0.60
ITGA2B P08514 2/20 0.60
SLC7A5 Q01650 4/20 0.58
PCNA P12004 1/20 0.47
LNPEP Q9UIQ6 2/20 0.47
ERAP2 Q6P179 1/20 0.46
GSR P00390 1/20 0.45
PTPN1 P18031 1/20 0.45
PTGS1 P23219 2/20 0.43
ALPI P09923 1/20 0.43
PKM P14618 1/20 0.43
XIAP P98170 1/20 0.43
LTA4H P09960 1/20 0.43
THRB P10828 1/20 0.42
MMP2 P08253 1/20 0.42
KDM4E B2RXH2 1/20 0.42
USP2 O75604 1/20 0.42
EGFR P00533 1/20 0.42
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL571283 0.95 ITGB3 (0.65) ITGB3ITGA2BSLC7A5LNPEPGSR
Cysteine SCHEMBL9755060 0.89 ITGB3 (0.58) ITGB3ITGA2BSLC7A5LNPEPGSR
Glutamic Acid SCHEMBL1696963 0.88 ITGB3 (0.57) ITGB3ITGA2BSLC7A5LNPEPGSR
Leucine SCHEMBL4586599 0.87 ITGB3 (0.56) ITGB3ITGA2BSLC7A5LNPEPERAP2
Tyrosine SCHEMBL3303402 0.87 SLC7A5 (0.73) ITGB3ITGA2BSLC7A5PCNALNPEP
SCHEMBL60228 0.87 SLC7A5 (0.73) ITGB3ITGA2BSLC7A5PCNAPTPN1
SCHEMBL11676390 0.87 SLC7A5 (0.73) ITGB3ITGA2BSLC7A5PCNAPTPN1
SCHEMBL10978818 0.87 SLC7A5 (0.73) ITGB3ITGA2BSLC7A5PCNAPTPN1
Tyrosine SCHEMBL21925058 0.87 SLC7A5 (0.73) ITGB3ITGA2BSLC7A5PCNALNPEP
SCHEMBL11370023 0.87 SLC7A5 (0.73) ITGB3ITGA2BSLC7A5PCNAPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116063253-B Biodegradable epoxy cross-linking agent and preparation method and application thereof 长春圣博玛生物材料有限公司 2023-07-21 CN disclosed
CN-116063253-A Biodegradable epoxy cross-linking agent and preparation method and application thereof 长春圣博玛生物材料有限公司 2023-05-05 CN disclosed
EP-1740601-B1 MYOSIN LIGHT CHAIN KINASE INHIBITORS AND THEIR USE UNIV CHICAGO (US) 2012-12-05 EP disclosed
US-20100016242-A1 MYOSIN LIGHT CHAIN KINASE INHIBITORS AND METHODS OF USE THE UNIVERSITY OF CHICAGO (US) 2010-01-21 US disclosed
US-7585844-B2 Comprising nonapeptide wherein first three amino acids and last three amino acids of sequence comprise basic amino acids, and wherein inhibitor comprises at least one D-amino acid or at least one non-hydrolyzable bond; may be used to treat intestinal diseases; infectious, ischemic, inflammatory disease THE UNIVERSITY OF CHICAGO (US) 2009-09-08 US disclosed
US-20050261196-A1 Myosin light chain kinase inhibitors and methods of use THE UNIVERSITY OF CHICAGO (US) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261196-A1 Myosin light chain kinase inhibitors and methods of use MYLK, MYLK2, MYLK3 ITGB3 1566/4885ITGA2B 1470/4885SLC7A5 4357/4885
US-20100016242-A1 MYOSIN LIGHT CHAIN KINASE INHIBITORS AND METHODS OF USE MYLK, MYLK2, MYLK3 ITGB3 1566/4885ITGA2B 1470/4885SLC7A5 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.